

References and Acknowledgements for Pathways Fall 2019

Obesity's Impact by Paula Stewart

References

1. Handa Y, et al. Estrogen concentrations in beef and human hormone dependent cancers. *Ann Oncology*. 2009 Sep;20(9):1610-1.
2. Simmons AL, et al. What are we putting in our food that is making us fat? Food additives, contaminants, and other putative contributors to obesity. *Curt Obes Rep*. 2014 Jun 1;3(2):273-285.
3. Basaranoglu M, et al. Carbohydrate intake and non-alcoholic fatty liver disease: fructose as a weapon of mass destruction. *Hepato-biliary Surg Nutr*. 2015 April; 4(2):109-16.
4. Suez J, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature*(2014)doi:10.1038/nature13793
5. Flegal KM, et al. Prevalence and trends in obesity among US adults, 1999 through 2008. *JAMA*. 2010; 303:235-241.
6. Anderson EL, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. *PLoS One*. 2015 Oct 29;10(10):e0140908
7. Ridner SH, et al. Body mass index and breast cancer treatment related lymphedema. *Support Care Cancer*. 2011 Jun;19(6):853-7.
8. Helyer LK, et al. Obesity is a risk factor for developing post operative lymphedema in breast cancer patients. *Breast J*. 2010; 16:48-54.
9. Weitman ES, et al. Obesity impairs lymphatic fluid transport and dendritic cell migration to lymph nodes. *PLoS One*. 2013; 8:e70703.
10. Zampell JC, et al. Regulation of adipogenesis by lymphatic fluid stasis: adipogenesis, fibrosis, and inflammation. *Plast Reconstruct Surg*. 2012; 129:838-847
11. Galic S, et al. Adipose tissue as an endocrine Organ. *Mol Cell Endocrinol*. 2010 Mar 25;316(2):129-39.
12. Rockson SG, et al. Estimating the population burden of lymphedema. *Ann N Y Acad Sci*. 2008;1131:147-154.
13. Kwan ML, et al. Exercise in patients with lymphedema: a systematic review of the contemporary literature. *J Cancer Surviv*. 2011; 5:320-336.
14. Noto H, et al. Low – carbohydrate diet and all cause mortality: a systematic review and meta-analysis of observational studies. *PLoS One*. 2013;8(1):e55030

Health Economics by Nicole Stout

References

1. Sloan, F. A., & Hsieh, C. R. (2017). *Health economics*. MIT Press.
 2. Armer, J. M., Feldman, J. L., Ostby, P. L., Chance-Hetzler, J. S., Sun, Y. A., Armer, N. C., & Shih, Y. C. T. (2018). Lymphedema Within the Healthcare System. In *Lymphedema*(pp. 503-523). Springer, Cham.
 3. Basta, M. N., Fox, J. P., Kanchwala, S. K., Wu, L. C., Serletti, J. M., Kovach, S. J., ... & Fischer, J. P. (2016). Complicated breast cancer–related lymphedema: evaluating health care resource utilization and associated costs of management. *The American Journal of Surgery*, 211(1), 133-141.
 4. Stout, N. L., Pfalzer, L. A., Springer, B., Levy, E., McGarvey, C. L., Danoff, J. V., ... & Soballe, P. W. (2012). Breast cancer–related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. *Physical therapy*, 92(1), 152-163.
 5. Karaca-Mandic, P., Hirsch, A. T., Rockson, S. G., & Ridner, S. H. (2015). The cutaneous, net clinical, and health economic benefits of advanced pneumatic compression devices in patients with lymphedema. *JAMA dermatology*, 151(11), 1187-1193.
 6. Boyages, J., Xu, Y., Kalfa, S., Koelmeyer, L., Parkinson, B., Mackie, H., ... & Taksá, L. (2017). Financial cost of lymphedema borne by women with breast cancer. *Psycho-oncology*, 26(6), 849-855.
 7. Stout Gergich, N. L., Pfalzer, L. A., McGarvey, C., Springer, B., Gerber, L. H., & Soballe, P. (2008). Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 112(12), 2809-2819.
 8. Schroeder, S. A. (2007). We can do better—improving the health of the American people. *New England Journal of Medicine*, 357(12), 1221-1228.
- † World Health Organization – Social Determinants of Health.
https://www.who.int/social_determinants/en/
- ‡Arsenault, K., Rielly, L., & Wise, H. (2011). Effects of complete decongestive therapy on the incidence rate of hospitalization for the management of recurrent cellulitis in adults with lymphedema. *Rehabilitation oncology*, 29(3), 14-20.

Prospective Surveillance by Jill Binkley

References

1. Schmitz KH, Stout NL, Andrews K, Binkley JM, Smith RA. Prospective evaluation of physical rehabilitation needs in breast cancer survivors: A call to action. *Cancer*. 2012;118(8 Suppl):2187-2190.
2. Schmitz KH, Speck RM, Rye SA, Disipio T, Hayes SC. Prevalence of breast cancer treatment sequelae over 6 years of follow-up: The Pulling Through Study. *Cancer*. 2012;118(8 Suppl):2217-2225.
3. Campbell KL, Pusic AL, Zucker DS, et al. A prospective model of care for breast cancer rehabilitation: function. *Cancer*. 2012;118(8 Suppl):2300-2311.
4. Springer BA, Levy E, McGarvey C, et al. Pre-operative assessment enables early diagnosis and recovery of shoulder function in patients with breast cancer. *Breast Cancer Res Treat*. 2010;120(1):135-147.
5. Stout Gergich NL, Pflazer LA, McGarvey C, Springer B, Gerber LH, Soballe P. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. *Cancer*. 2008;112(12):2809-2819.
6. Stout NL, Binkley JM, Schmitz KH, et al. A prospective surveillance model for rehabilitation for women with breast cancer. *Cancer*. 2012;118(8 Suppl):2191-2200.
7. Hayes SC, Johansson K, Stout NL, et al. Upper-body morbidity after breast cancer: Incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. *Cancer*. 2012;118(8 Suppl):2237-2249.
8. Stout NL, Binkley JM, Schmitz KH, et al. A prospective surveillance model for rehabilitation for women with breast cancer. *Cancer*. 2012;118(8 Suppl):2191-2200.
9. Cheville AL, Tchou J. Barriers to rehabilitation following surgery for primary breast cancer. *J Surg Oncol*. 2007;95(5):409-418.
10. Binkley JM, Harris SR, Levangie PK, et al. Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. *Cancer*. 2012;118(8 Suppl):2207-2216.
11. Torres Lacomba M, Yuste Sánchez MJ, Zapico Goñi A, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. *BMJ*. 2010;340:b5396.
12. Levenhagen K, Davies C, Perdomo M, Ryans K, Gilchrist L. Diagnosis of upper quadrant lymphedema secondary to cancer: clinical practice guideline from the Oncology Section of the American Physical Therapy Association. *Phys Ther*. 2017;97(7):729-745.
13. Yahathugoda C, Weiler MJ, Rao R, et al. Use of a Novel Portable Three-Dimensional Imaging System to Measure Limb Volume and Circumference in Patients with Filarial Lymphedema. *Am J Trop Med Hyg*. 2017;97(6):1836-1842.
14. Binkley J, Weiler M, Frank N, Bober L, Dixon J, Stratford P. Reliability and Convergent Validity of the LymphaTech System to Assess Arm Volume in Patients During and After Treatment for Breast Cancer. *Phys Ther*. 2019; Accepted for Publication.

15. Chatman AB, Hyams SP, Neel JM, et al. The Patient-Specific Functional Scale: measurement properties in patients with knee dysfunction. *Phys Ther.* 1997;77(8):820-829.
16. Binkley JM, Stratford P, Kirkpatrick S, Farley CR, Okoli J, Gabram S. Estimating the Reliability and Validity of the Upper Extremity Functional Index in Women After Breast Cancer Surgery. *Clin Breast Cancer.* 2018.
17. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. *J Clin Oncol.* 1997;15(3):974-986.
18. Lai L, Binkley J, Jones V, et al. Implementing the Prospective Surveillance Model (PSM) of Rehabilitation for Breast Cancer Patients with 1-Year Postoperative Follow-up, a Prospective, Observational Study. *Ann Surg Oncol.* 2016;23(10):3379-3384.
19. Binkley JM, Harris SR, Levangie PK, et al. Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. *Cancer.* 2012;118(8 Suppl):2207-2216.

Highlights from the 2019 ILF Conference in Chicago by Anna Towers and Anna Kennedy

References

1. Debunking Lymphedema Risk-Reduction Behaviours: Risky Conclusions. *Journal of Clinical Oncology*, Vol 34, No 25 (September 1), 2016: pp 3109
2. *Lymphat Res Biol*. 2016 Sep;14(3):124-6. doi: 10.1089/lrb.2016.0027.
3. Lymphedema Risk Reduction Practices. National Lymphedema Network 2011.
4. SBrS 2018: Early Detection and Intervention Effective for Preventing Breast Cancer-Related Lymphedema

Scientific research developments by Pierre-Yves von der Weid

References

1. Liao S, von der Weid P-Y. (2015) Lymphatic system: an active pathway for immune protection. *Semin Cell Dev Biol.* 38:83-89.
2. Padera TP, Meijer EF, Munn LL. (2016) The Lymphatic System in Disease Processes and Cancer Progression. *Annu Rev Biomed Eng.* 18:125-58.
3. Stephens M, Liao S, von der Weid P-Y. (2019) Mesenteric lymphatic alterations observed during DSS induced intestinal inflammation are driven in a TLR4-PAMP/DAMP discriminative manner. *Front Immunol*, 10:557. doi: 10.3389/fimmu.2019.00557.
4. Rehal S, Stephens M, Roizes S, Liao S, von der Weid P-Y. (2018) Acute intestinal inflammation irreversibly damages the mesenteric lymphatic system and alters DC tissue retention. *Am J Physiol Gastrointest Liver Physiol*, 314:G408–G417.
5. Rehal S, von der Weid P-Y. (2017) TNF Δ ARE mice display abnormal lymphatics and develop tertiary lymphoid organs in the mesentery. *Am J Pathol*, 187:798-807.
6. Lin Y, Louie D, Ganguly A, Wu D, Huang P, Liao S. Elastin shapes small molecule distribution in lymph node conduits. *J Immunol.* 2018 May 1;200:3142-3150. doi: 10.4049/jimmunol.1800074